Approval · Notice of Compliance 18782 · 2016
REPAGLINIDE: Notice of Compliance 18782
Issued December 16, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18782
- Date
- December 16, 2016
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- GLUCONORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REPAGLINIDE | 02415968 | Marketed |
| REPAGLINIDE | 02415976 | Marketed |
| REPAGLINIDE | 02415984 | Marketed |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB